Literature DB >> 20103664

Inherited determinants of ovarian cancer survival.

Ellen L Goode1, Matthew J Maurer, Thomas A Sellers, Catherine M Phelan, Kimberly R Kalli, Brooke L Fridley, Robert A Vierkant, Sebastian M Armasu, Kristin L White, Gary L Keeney, William A Cliby, David N Rider, Linda E Kelemen, Monica B Jones, Prema P Peethambaram, Johnathan M Lancaster, Janet E Olson, Joellen M Schildkraut, Julie M Cunningham, Lynn C Hartmann.   

Abstract

PURPOSE: Due to variation of outcome among cases, we sought to examine whether overall survival in ovarian cancer was associated with common inherited variants in 227 candidate genes from ovarian cancer-related pathways including angiogenesis, inflammation, detoxification, glycosylation, one-carbon transfer, apoptosis, cell cycle regulation, and cellular senescence. EXPERIMENTAL
DESIGN: Blood samples were obtained from 325 women with invasive epithelial ovarian cancer diagnosed at the Mayo Clinic from 1999 to 2006. During a median follow-up of 3.8 years (range, 0.1-8.6 years), 157 deaths were observed. Germline DNA was analyzed at 1,416 single nucleotide polymorphisms (SNP). For all patients, and for 203 with serous subtype, we assessed the overall significance of each gene and pathway, and estimated risk of death via hazard ratios (HR) and 95% confidence intervals (CI), adjusting for known prognostic factors.
RESULTS: Variation within angiogenesis was most strongly associated with survival time overall (P = 0.03) and among patients with serous cancer (P = 0.05), particularly for EIF2B5 rs4912474 (all patients HR, 0.69; 95% CI, 0.54-0.89; P = 0.004), VEGFC rs17697305 (serous subtype HR, 2.29; 95% CI, 1.34-3.92; P = 0.003), and four SNPs in VHL. Variation within the inflammation pathway was borderline significant (all patients, P = 0.09), and SNPs in CCR3, IL1B, IL18, CCL2, and ALOX5 which correlated with survival time are worthy of follow-up.
CONCLUSION: An extensive multiple-pathway assessment found evidence that inherited differences may play a role in outcome of ovarian cancer patients, particularly in genes within the angiogenesis and inflammation pathways. Our work supports efforts to target such mediators for therapeutic gain.

Entities:  

Mesh:

Year:  2010        PMID: 20103664      PMCID: PMC2818685          DOI: 10.1158/1078-0432.CCR-09-2553

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  46 in total

Review 1.  Mapping complex disease loci in whole-genome association studies.

Authors:  Christopher S Carlson; Michael A Eberle; Leonid Kruglyak; Deborah A Nickerson
Journal:  Nature       Date:  2004-05-27       Impact factor: 49.962

Review 2.  Cancer of the ovary.

Authors:  Stephen A Cannistra
Journal:  N Engl J Med       Date:  2004-12-09       Impact factor: 91.245

3.  A tail strength measure for assessing the overall univariate significance in a dataset.

Authors:  Jonathan Taylor; Robert Tibshirani
Journal:  Biostatistics       Date:  2005-12-06       Impact factor: 5.899

Review 4.  Reactive oxygen species in tumor progression.

Authors:  Peter Storz
Journal:  Front Biosci       Date:  2005-05-01

Review 5.  MUC1 and the MUCs: a family of human mucins with impact in cancer biology.

Authors:  Stephan E Baldus; Katja Engelmann; Franz-Georg Hanisch
Journal:  Crit Rev Clin Lab Sci       Date:  2004       Impact factor: 6.250

6.  The effects of common genetic variants in oncogenes on ovarian cancer survival.

Authors:  Lydia Quaye; Simon A Gayther; Susan J Ramus; Richard A Di Cioccio; Valerie McGuire; Estrid Hogdall; Claus Hogdall; Jan Blaakr; Douglas F Easton; Bruce A J Ponder; Ian Jacobs; Susanne Kruger Kjaer; Alice S Whittemore; Celeste Leigh Pearce; Paul D P Pharoah; Honglin Song
Journal:  Clin Cancer Res       Date:  2008-09-15       Impact factor: 12.531

7.  Heterogeneity of mucin gene expression in normal and neoplastic tissues.

Authors:  S B Ho; G A Niehans; C Lyftogt; P S Yan; D L Cherwitz; E T Gum; R Dahiya; Y S Kim
Journal:  Cancer Res       Date:  1993-02-01       Impact factor: 12.701

8.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

9.  Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades.

Authors:  Jill S Barnholtz-Sloan; Ann G Schwartz; Faisal Qureshi; Suzanne Jacques; John Malone; Adnan R Munkarah
Journal:  Am J Obstet Gynecol       Date:  2003-10       Impact factor: 8.661

10.  Epithelial ovarian cancer: the role of cell cycle genes in the different histotypes.

Authors:  Giuseppina D'Andrilli; Antonio Giordano; Alessandro Bovicelli
Journal:  Open Clin Cancer J       Date:  2008-02-06
View more
  37 in total

1.  Negative regulation of HIF-1α by an FBW7-mediated degradation pathway during hypoxia.

Authors:  Jessica M Cassavaugh; Sarah A Hale; Theresa L Wellman; Alan K Howe; Cheung Wong; Karen M Lounsbury
Journal:  J Cell Biochem       Date:  2011-12       Impact factor: 4.429

2.  Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer.

Authors:  Keith L Knutson; Matthew J Maurer; Claudia C Preston; Kirsten B Moysich; Krista Goergen; Kieran M Hawthorne; Julie M Cunningham; Kunle Odunsi; Lynn C Hartmann; Kimberly R Kalli; Ann L Oberg; Ellen L Goode
Journal:  Cancer Immunol Immunother       Date:  2015-08-23       Impact factor: 6.968

3.  Ovarian cancer risk associated with inherited inflammation-related variants.

Authors:  Kristin L White; Joellen M Schildkraut; Rachel T Palmieri; Edwin S Iversen; Andrew Berchuck; Robert A Vierkant; David N Rider; Bridget Charbonneau; Mine S Cicek; Rebecca Sutphen; Michael J Birrer; Paul P D Pharoah; Honglin Song; Jonathan Tyrer; Simon A Gayther; Susan J Ramus; Nicolas Wentzensen; Hannah P Yang; Montserrat Garcia-Closas; Catherine M Phelan; Julie M Cunningham; Brooke L Fridley; Thomas A Sellers; Ellen L Goode
Journal:  Cancer Res       Date:  2012-01-26       Impact factor: 12.701

Review 4.  Targeted immune therapy of ovarian cancer.

Authors:  Keith L Knutson; Lavakumar Karyampudi; Purushottam Lamichhane; Claudia Preston
Journal:  Cancer Metastasis Rev       Date:  2015-03       Impact factor: 9.264

5.  Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib.

Authors:  Vincenzo Marotta; Concetta Sciammarella; Mario Capasso; Alessandro Testori; Claudia Pivonello; Maria Grazia Chiofalo; Rosario Pivonello; Luciano Pezzullo; Gerardo Botti; Annamaria Colao; Antongiulio Faggiano
Journal:  Endocrine       Date:  2016-12-16       Impact factor: 3.633

6.  Xenobiotic-Metabolizing gene polymorphisms and ovarian cancer risk.

Authors:  Ellen L Goode; Kristin L White; Robert A Vierkant; Catherine M Phelan; Julie M Cunningham; Joellen M Schildkraut; Andrew Berchuck; Melissa C Larson; Brooke L Fridley; Janet E Olson; Penelope M Webb; Xiaoqing Chen; Jonathan Beesley; Georgia Chenevix-Trench; Thomas A Sellers
Journal:  Mol Carcinog       Date:  2010-12-28       Impact factor: 4.784

7.  Inherited variants in mitochondrial biogenesis genes may influence epithelial ovarian cancer risk.

Authors:  Jennifer Permuth-Wey; Y Ann Chen; Ya-Yu Tsai; Zhihua Chen; Xiaotao Qu; Johnathan M Lancaster; Heather Stockwell; Getachew Dagne; Edwin Iversen; Harvey Risch; Jill Barnholtz-Sloan; Julie M Cunningham; Robert A Vierkant; Brooke L Fridley; Rebecca Sutphen; John McLaughlin; Steven A Narod; Ellen L Goode; Joellen M Schildkraut; David Fenstermacher; Catherine M Phelan; Thomas A Sellers
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-03-29       Impact factor: 4.254

8.  Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk.

Authors:  Ernest K Amankwah; Hui-Yi Lin; Jonathan P Tyrer; Kate Lawrenson; Joe Dennis; Ganna Chornokur; Katja K H Aben; Hoda Anton-Culver; Natalia Antonenkova; Fiona Bruinsma; Elisa V Bandera; Yukie T Bean; Matthias W Beckmann; Maria Bisogna; Line Bjorge; Natalia Bogdanova; Louise A Brinton; Angela Brooks-Wilson; Clareann H Bunker; Ralf Butzow; Ian G Campbell; Karen Carty; Zhihua Chen; Y Ann Chen; Jenny Chang-Claude; Linda S Cook; Daniel W Cramer; Julie M Cunningham; Cezary Cybulski; Agnieszka Dansonka-Mieszkowska; Andreas du Bois; Evelyn Despierre; Ed Dicks; Jennifer A Doherty; Thilo Dörk; Matthias Dürst; Douglas F Easton; Diana M Eccles; Robert P Edwards; Arif B Ekici; Peter A Fasching; Brooke L Fridley; Yu-Tang Gao; Aleksandra Gentry-Maharaj; Graham G Giles; Rosalind Glasspool; Marc T Goodman; Jacek Gronwald; Patricia Harrington; Philipp Harter; Hanis N Hasmad; Alexander Hein; Florian Heitz; Michelle A T Hildebrandt; Peter Hillemanns; Claus K Hogdall; Estrid Hogdall; Satoyo Hosono; Edwin S Iversen; Anna Jakubowska; Allan Jensen; Bu-Tian Ji; Beth Y Karlan; Heather Jim; Melissa Kellar; Lambertus A Kiemeney; Camilla Krakstad; Susanne K Kjaer; Jolanta Kupryjanczyk; Diether Lambrechts; Sandrina Lambrechts; Nhu D Le; Alice W Lee; Shashi Lele; Arto Leminen; Jenny Lester; Douglas A Levine; Dong Liang; Boon Kiong Lim; Jolanta Lissowska; Karen Lu; Jan Lubinski; Lene Lundvall; Leon F A G Massuger; Keitaro Matsuo; Valerie McGuire; John R McLaughlin; Ian McNeish; Usha Menon; Roger L Milne; Francesmary Modugno; Kirsten B Moysich; Roberta B Ness; Heli Nevanlinna; Ursula Eilber; Kunle Odunsi; Sara H Olson; Irene Orlow; Sandra Orsulic; Rachel Palmieri Weber; James Paul; Celeste L Pearce; Tanja Pejovic; Liisa M Pelttari; Jennifer Permuth-Wey; Malcolm C Pike; Elizabeth M Poole; Harvey A Risch; Barry Rosen; Mary Anne Rossing; Joseph H Rothstein; Anja Rudolph; Ingo B Runnebaum; Iwona K Rzepecka; Helga B Salvesen; Eva Schernhammer; Ira Schwaab; Xiao-Ou Shu; Yurii B Shvetsov; Nadeem Siddiqui; Weiva Sieh; Honglin Song; Melissa C Southey; Beata Spiewankiewicz; Lara Sucheston-Campbell; Soo-Hwang Teo; Kathryn L Terry; Pamela J Thompson; Lotte Thomsen; Ingvild L Tangen; Shelley S Tworoger; Anne M van Altena; Robert A Vierkant; Ignace Vergote; Christine S Walsh; Shan Wang-Gohrke; Nicolas Wentzensen; Alice S Whittemore; Kristine G Wicklund; Lynne R Wilkens; Anna H Wu; Xifeng Wu; Yin-Ling Woo; Hannah Yang; Wei Zheng; Argyrios Ziogas; Linda E Kelemen; Andrew Berchuck; Joellen M Schildkraut; Susan J Ramus; Ellen L Goode; Alvaro N A Monteiro; Simon A Gayther; Steven A Narod; Paul D P Pharoah; Thomas A Sellers; Catherine M Phelan
Journal:  Genet Epidemiol       Date:  2015-09-24       Impact factor: 2.135

9.  MTHFR polymorphisms in relation to ovarian cancer risk.

Authors:  Kathryn L Terry; Shelley S Tworoger; Ellen L Goode; Margaret A Gates; Linda Titus-Ernstoff; Linda E Kelemen; Thomas A Sellers; Susan E Hankinson; Daniel W Cramer
Journal:  Gynecol Oncol       Date:  2010-11       Impact factor: 5.482

Review 10.  The immune system in the pathogenesis of ovarian cancer.

Authors:  Bridget Charbonneau; Ellen L Goode; Kimberly R Kalli; Keith L Knutson; Melissa S Derycke
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.